ACTU - NASDAQ
Actuate Therapeutics Inc
$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
At a Glance
Live Snapshotactu
Total Current Assets
Last Annual Value
13.64M
3-Year CAGR
-13%
5-Year CAGR
-8%
10-Year CAGR
-4%
Actuate Therapeutics Inc Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Actuate Therapeutics Inc NASDAQ:ACTU | 13.64M | 65.8% | N/A | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 60.13M | -8.1% | -16.3% | 4.4% | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 208.70M | -14.3% | -19.9% | 8.4% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 80.59M | 28.1% | 13.6% | 9.5% | |
 Spero Therapeutics, Inc. NASDAQ:SPRO | 67.29M | -20.0% | -15.7% | 18.9% | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 19.31M | 5.7% | -26.7% | N/A | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 49.38M | -34.5% | -30.5% | -13.0% | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 83.65M | 15.4% | -1.1% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 266.45M | -22.2% | -18.7% | 17.9% | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 82.08M | 67.4% | -4.6% | 57.8% | |
 Nkarta, Inc. NASDAQ:NKTX | 282.51M | 3.7% | 2.8% | N/A |
Actuate Therapeutics Inc Fair Value Envelope
Related Guides
Continue your ACTU research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.